JPH09500209A - 哺乳類の結合組織マトリックスの分解の指標としてのykl−40の検定方法 - Google Patents
哺乳類の結合組織マトリックスの分解の指標としてのykl−40の検定方法Info
- Publication number
- JPH09500209A JPH09500209A JP7504194A JP50419495A JPH09500209A JP H09500209 A JPH09500209 A JP H09500209A JP 7504194 A JP7504194 A JP 7504194A JP 50419495 A JP50419495 A JP 50419495A JP H09500209 A JPH09500209 A JP H09500209A
- Authority
- JP
- Japan
- Prior art keywords
- ykl
- serum
- patients
- immunoassay
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.診断を行うのに有意な濃度のYKL−40が哺乳類の生体試料中に存在し ているか否かを検出することからなる、哺乳類のYKL−40含有結合組織の分 解に関連する疾患状態の存在を確認する方法。 2.試料中のYKL−40の量を免疫検定法を用いて検出する請求の範囲1記 載の方法。 3.免疫検定方が競合免疫検定法である請求の範囲2記載の方法。 4.免疫検定法が、放射性同位元素、酵素、蛍光分子、化学発光分子、生物発 光分子およびコロイド金属からなる群から選択される検出可能な標識を利用して YKL−40を検出する請求の範囲3記載の方法。 5.疾患状態が、炎症性または退行性の間接疾患である請求の範囲1記載の方 法。 6.疾患が肝硬変である請求の範囲1記載の方法。 7.疾患状態が転移性癌である請求の範囲1記載の方法。 8.疾患状態が転移性乳癌である請求の範囲1記載の方法。 9.哺乳類がヒトである請求の範囲1記載の方法。 10.免疫検定方法がポリクロナール抗体を使用してYKL−40を検出する 請求の範囲2記載の方法。 11.免疫検定方法がモノクロナール抗体を使用してYKL−40を検出する 請求の範囲2記載の方法。 12.生体試料が、疾患状態になった組織である請求の範囲1記載の方法。 13.生体試料が血液、血清または血漿である請求の範囲12記 載の方法。 14.YKL−40が、癌が再発した後に患者から採取した血清の試料中に予 後を行うのに有意な濃度で存在しているのか否かを検出し測定することからなる 、癌が寛解後に再発した乳癌患者の生存期間の予後を示唆するデータを得る方法 。 15.データを得る方法が、血清試料中にYKL−40が存在していることを 、YKL−40に対して特異的な抗体に結合された検出可能な標識に提供される シグナルで示す競合免疫検定法からなる請求の範囲14記載の方法。 16.検出可能な標識が、放射性同位元素、酵素、蛍光分子、化学発光分子、 生物発光分子およびコロイド金属からなる群から選択される請求の範囲15記載 の方法。 17.抗体が、YKL−40に対して特異的に反応性であるポリクロナール抗 体である請求の範囲15記載の方法。 18.抗体が、YKL−40に対して特異的に反応性であるモノクロナール抗 体である請求の範囲15記載の方法。 19.哺乳類の生体試料中に存在するYKL−40の量の増減を検出すること からなる、哺乳類のYKL−40含有結合組織の分解に関連する疾患状態の経過 または改善を監視する方法。 20.試料中のYKL−40の量が免疫検定法を用いて検出される請求の範囲 19記載の方法。 21.免疫検定法が競合免疫検定法である請求の範囲20記載の方法。 22.免疫検定法が、放射性同位元素、酵素、蛍光分子、化学発光分子、生物 発光分子およびコロイド金属からなる群から選択される検出可能な標識を、シグ ナルとして使用してYKL−40を検出 する請求の範囲20記載の方法。 23.疾患が炎症または退行性の関節疾患である請求の範囲19記載の方法。 24.哺乳類がヒトである請求の範囲19記載の方法。 25.免疫検定方法がポリクロナール抗体を使用してYKL−40を検出する 請求の範囲21記載の方法。 26.免疫検定方法がモノクロナール抗体を使用してYKL−40を検出する 請求の範囲21記載の方法。 27.生体試料が、疾患状態になった組織から採取した体液または組織の試料 である請求の範囲26記載の方法。 28.非ヒト哺乳類の免疫下によって産生され、YKL−40に対して特異的 に反応性であるポリクロナール抗体。 29.非ヒト哺乳類から採取した細胞から形成されたハイブリドーマから産生 され、YKL−40に対して特異的に反応性であるモノクロナール抗体。 30.医薬として許容される担体中の治療上有効な投与量のYKL−40の基 分子を投与することからなる、組織中のYKL−40の活性を減少させることに よって、YKL−40含有結合組織の分解に関連する哺乳類の疾患状態を治療す る方法。 31.疾患状態が炎症または退行性の関節疾患であり、そしてYKL−40の 基分子が冒された関節の滑液中に投与される請求の範囲30記載の方法。 32.医薬として許容される担体中の治療上有効な投与量の抗YKL−40抗 体を投与することからなる、組織中のYKL−40の活性を減少させることによ って、YKL−40含有組織の分解に関連する哺乳類の疾患状態を治療する方法 。 33.疾患状態が炎症または退行性の関節疾患であり、そしてYKL−40の 基質分子が冒された関節の滑液中に投与される請求の範囲32記載の方法。 34.YKL−40抗体と免疫検定用試薬が入っている、請求の範囲1記載の 方法に用いるキット。 35.YKL−40抗体と免疫検定用試薬が入っている、請求の範囲20記載 の方法に用いるキット。 36.医薬として許容される担体中にYKL−40の基質分子を含有してなる 医薬組成物。 37.医薬として許容される担体中にYKL−40の抗体を含有してなる医薬 組成物。 38.免疫検定方法がサンドイッチ免疫検定法である請求の範囲2記載の方法 。 39.サンドイッチ免疫検定法が酵素結合イムノソルベント検定法である請求 の範囲38記載の方法。 40.免疫検定法がサンドイッチ免疫検定法である請求の範囲14記載の方法 。 41.サンドイッチ免疫検定法が酵素結合イムノソルベント検定法である請求 の範囲40記載の方法。 42.免疫検定法がサンドイッチ免疫検定法である請求の範囲20記載の方法 。 43.サンドイッチ免疫検定法が酵素結合イムノソルベント検定法である請求 の範囲42記載の方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8998993A | 1993-07-09 | 1993-07-09 | |
US89,989 | 1993-07-09 | ||
US08/089,989 | 1993-07-09 | ||
PCT/US1994/007754 WO1995001995A1 (en) | 1993-07-09 | 1994-07-08 | Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09500209A true JPH09500209A (ja) | 1997-01-07 |
JP2878455B2 JP2878455B2 (ja) | 1999-04-05 |
Family
ID=22220557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7504194A Expired - Lifetime JP2878455B2 (ja) | 1993-07-09 | 1994-07-08 | 哺乳類の結合組織マトリックスの分解の指標としてのykl−40の検定方法 |
Country Status (6)
Country | Link |
---|---|
US (4) | US5935798A (ja) |
EP (1) | EP0710251B1 (ja) |
JP (1) | JP2878455B2 (ja) |
CA (2) | CA2164498C (ja) |
DE (1) | DE69434230T2 (ja) |
WO (1) | WO1995001995A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011510307A (ja) * | 2008-01-23 | 2011-03-31 | ヘルレフ ホスピタル | 不特定疾患の汎用マーカーとしてのykl−40 |
JP2012502284A (ja) * | 2008-09-15 | 2012-01-26 | ヘルレフ ホスピタル | 疾患の処置及び監視の選択用マーカーとしてのykl−40 |
US8486143B2 (en) | 2009-05-22 | 2013-07-16 | Soft Tissue Regeneration, Inc. | Mechanically competent scaffold for ligament and tendon regeneration |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7229770B1 (en) | 1998-10-01 | 2007-06-12 | The Regents Of The University Of California | YKL-40 as a marker and prognostic indicator for cancers |
CA2164498C (en) | 1993-07-09 | 2007-09-11 | Paul A. Price | Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices |
IL115744A (en) * | 1994-10-27 | 2000-07-16 | Akzo Nobel Nv | Peptides comprising a subsequence of human cartilage glycoprotein - 39 |
US5773259A (en) * | 1996-03-20 | 1998-06-30 | Smithkline Beecham Corporation | Tissue remodeling proteins |
US5843449A (en) * | 1996-03-25 | 1998-12-01 | Akzo Nobel N.V. | Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases |
US6881824B1 (en) | 1996-04-24 | 2005-04-19 | Akzo Nobel N.V. | Peptides suitable for use in antigen specific immunosuppressive therapy |
IL120561A0 (en) | 1996-04-24 | 1997-07-13 | Akzo Nobel Nv | Peptides suitable for use in immunosuppressive therapy |
US5726061A (en) * | 1996-10-08 | 1998-03-10 | Smithkline Beechum Corporation | Method of diagnosing and monitoring colorectal cancer |
AU3116800A (en) * | 1998-12-11 | 2000-06-26 | Research Foundation Of The State University Of New York, The | Compositions and methods for altering cell migration |
DE60026150T2 (de) | 1999-08-30 | 2006-11-16 | Interleukin Genetics, Inc., Waltham | Diagnostika und therapeutika für osteoporose |
EP1319184B1 (en) | 2000-08-14 | 2007-07-25 | N.V. Organon | Use of antibodies against specific mhc-peptide complexes |
US6631330B1 (en) * | 2000-08-21 | 2003-10-07 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers |
AU7812800A (en) * | 2000-08-21 | 2002-03-04 | Epigene | Diagnosis method of fibrotic disease using biochemical markers |
CA2454342A1 (en) * | 2001-07-24 | 2003-02-06 | Yale University | Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease |
KR20060061350A (ko) | 2003-08-08 | 2006-06-07 | 인터레우킨 제네틱스, 인코포레이티드 | 골다공증 진단 및 치료 |
WO2005039487A2 (en) * | 2003-09-10 | 2005-05-06 | Sloan-Kettering Institute For Cancer Research | Method for early detection of ovarian cancer |
WO2005081980A2 (en) * | 2004-02-25 | 2005-09-09 | Medimmune, Inc. | Methods and compositions relating to chitinases and chitinase-like molecules and modulation of osteoclasts |
WO2006016110A1 (en) * | 2004-08-10 | 2006-02-16 | University College Cardiff Consultants Limited | Methods and kit for the prognosis of breast cancer |
DE602006019205D1 (de) * | 2005-02-28 | 2011-02-10 | Bio Y As | Monoklonale ykl-40-antikörper |
EP1928496A4 (en) * | 2005-08-31 | 2011-01-05 | Medimmune Inc | C / CLP ANTAGONISTS AND METHOD OF USE |
US20110143380A1 (en) * | 2006-03-14 | 2011-06-16 | The Washington University | Alzheimer's disease biomarkers and methods of use |
EP2450710B1 (en) | 2006-07-14 | 2020-09-02 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
NZ586746A (en) * | 2008-01-23 | 2012-07-27 | Righospitalet | Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40 |
CN101587125B (zh) * | 2008-05-21 | 2013-07-24 | 林标扬 | 高表达癌症标记物和低表达组织器官标记物组合试剂盒 |
US11480574B2 (en) * | 2008-05-21 | 2022-10-25 | Biaoyang Lin | Reagent kits for diagnosis of hepatocarcinoma |
EP2340437A1 (en) | 2008-09-15 | 2011-07-06 | Herlev Hospital | Ykl-40 as a marker for gastrointestinal cancers |
EP2564200B8 (en) | 2010-04-27 | 2019-10-02 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
WO2012136548A1 (en) * | 2011-04-04 | 2012-10-11 | Universiteit Gent | Biomarkers for acute kidney injury |
WO2016090323A1 (en) | 2014-12-05 | 2016-06-09 | Prelude, Inc. | Dcis recurrence and invasive breast cancer |
RU2623869C1 (ru) * | 2016-07-29 | 2017-06-29 | Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский государственный университет" (ТГУ, НИ ТГУ) | Способ прогнозирования безрецидивной выживаемости у больных раком молочной железы |
AU2019339508A1 (en) | 2018-09-14 | 2021-04-15 | Prelude Corporation | Method of selection for treatment of subjects at risk of invasive breast cancer |
EP3876987A4 (en) * | 2018-11-07 | 2022-09-14 | Brown University | METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS FOR THE TREATMENT OF FIBROSIS |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4628027A (en) * | 1982-05-19 | 1986-12-09 | Molecular Engineering Associates, Ltd. | Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins |
GB8516081D0 (en) * | 1985-06-25 | 1985-07-31 | Ciba Geigy Ag | Assay & purification of amyloid components |
JPS6323898A (ja) * | 1986-07-16 | 1988-02-01 | Dainippon Pharmaceut Co Ltd | 新規ポリペプチド及びそれをコ−ドするdna並びにそれらの製法 |
US4782017A (en) * | 1986-08-25 | 1988-11-01 | Eastman Kodak Company | Analytical element and method for determination of theophylline by enzyme inhibition |
WO1990008195A1 (en) * | 1989-01-13 | 1990-07-26 | President And Fellows Of Harvard College | Monoclonal antibody to human type ix collagen |
AU648505B2 (en) * | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
US5427954A (en) * | 1992-04-29 | 1995-06-27 | Shriner's Hospitals For Crippled Children | Compositions and methods for detection and treatment of human osteoarthritis |
CA2164498C (en) | 1993-07-09 | 2007-09-11 | Paul A. Price | Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices |
US5773259A (en) * | 1996-03-20 | 1998-06-30 | Smithkline Beecham Corporation | Tissue remodeling proteins |
EP0805206A3 (en) | 1996-05-03 | 1999-09-15 | Smithkline Beecham Corporation | Human cartilage glycoprotein |
WO1998006859A1 (en) | 1996-08-09 | 1998-02-19 | Human Genome Sciences, Inc. | Human chitinase alpha and chitinase alpha-2 |
US5811535A (en) | 1996-08-09 | 1998-09-22 | Smithkline Beecham Corporation | Human cartilege gp39-like gene |
US5726061A (en) | 1996-10-08 | 1998-03-10 | Smithkline Beechum Corporation | Method of diagnosing and monitoring colorectal cancer |
-
1993
- 1993-07-12 CA CA002164498A patent/CA2164498C/en not_active Expired - Lifetime
-
1994
- 1994-07-08 WO PCT/US1994/007754 patent/WO1995001995A1/en active IP Right Grant
- 1994-07-08 US US08/581,527 patent/US5935798A/en not_active Expired - Lifetime
- 1994-07-08 JP JP7504194A patent/JP2878455B2/ja not_active Expired - Lifetime
- 1994-07-08 DE DE69434230T patent/DE69434230T2/de not_active Expired - Lifetime
- 1994-07-08 EP EP94925091A patent/EP0710251B1/en not_active Expired - Lifetime
- 1994-07-08 CA CA002166292A patent/CA2166292C/en not_active Expired - Lifetime
-
1998
- 1998-12-18 US US09/215,077 patent/US6794150B2/en not_active Expired - Fee Related
-
1999
- 1999-03-04 US US09/262,213 patent/US6579684B2/en not_active Expired - Fee Related
-
2003
- 2003-08-25 US US10/648,811 patent/US7230086B2/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011510307A (ja) * | 2008-01-23 | 2011-03-31 | ヘルレフ ホスピタル | 不特定疾患の汎用マーカーとしてのykl−40 |
JP2012502284A (ja) * | 2008-09-15 | 2012-01-26 | ヘルレフ ホスピタル | 疾患の処置及び監視の選択用マーカーとしてのykl−40 |
US8486143B2 (en) | 2009-05-22 | 2013-07-16 | Soft Tissue Regeneration, Inc. | Mechanically competent scaffold for ligament and tendon regeneration |
US8758437B2 (en) | 2009-05-22 | 2014-06-24 | Soft Tissue Regeneration, Inc. | Mechanically competent scaffold for ligament and tendon regeneration |
Also Published As
Publication number | Publication date |
---|---|
CA2164498A1 (en) | 1995-01-19 |
US6794150B2 (en) | 2004-09-21 |
JP2878455B2 (ja) | 1999-04-05 |
US5935798A (en) | 1999-08-10 |
EP0710251A4 (en) | 1997-12-10 |
DE69434230D1 (de) | 2005-02-17 |
US6579684B2 (en) | 2003-06-17 |
CA2166292C (en) | 2007-04-17 |
WO1995001995A1 (en) | 1995-01-19 |
EP0710251B1 (en) | 2005-01-12 |
US20050065325A1 (en) | 2005-03-24 |
DE69434230T2 (de) | 2005-12-08 |
CA2164498C (en) | 2007-09-11 |
EP0710251A1 (en) | 1996-05-08 |
CA2166292A1 (en) | 1995-01-19 |
US20020090658A1 (en) | 2002-07-11 |
US20020031793A1 (en) | 2002-03-14 |
US7230086B2 (en) | 2007-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2878455B2 (ja) | 哺乳類の結合組織マトリックスの分解の指標としてのykl−40の検定方法 | |
US7670599B2 (en) | YKL-40 as a marker and prognostic indicator for cancers | |
RU2137130C1 (ru) | Способ раннего определения, определения тяжести заболевания и оценка процесса лечения сепсиса, а также средства для осуществления указанного способа | |
US7094580B2 (en) | Methods for producing pure perlecan and other heparan sulfate proteoglycans | |
CN103694332B (zh) | 一种新的肿瘤标志物 | |
JP5231477B2 (ja) | 関節炎の診断および治療のためのグルコース−6−ホスフェートイソメラーゼおよびその抗体の使用、ならびに抗関節炎化合物の試験 | |
JP5364086B2 (ja) | 変形性関節症と関節リウマチ及び無病状態とを鑑別するための軟骨中間層タンパク質2c1及びその使用 | |
JP2000512123A (ja) | ネフロパシー―関連免疫グロブリンg及びそのための抗体 | |
US5367063A (en) | Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis | |
EP1766411B1 (en) | Method for determining a tissue degradation process by detection of comp neoepitopes | |
JPWO2007145192A1 (ja) | Iv型コラーゲン様免疫活性ペプチド | |
CN101317089A (zh) | 聚集蛋白聚糖及其片段的检测或定量 | |
JP4414023B2 (ja) | 関節炎関連メラノトランスフェリンの測定方法および試薬 | |
WO1995002188A1 (en) | Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices | |
WO2000055187A1 (en) | Therapeutic and diagnostic applications of p400: a newly discovered beta-amyloid binding protein present in human biological fluids | |
WO2002036826A2 (en) | Del-1 and benign prostatic hyperplasia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090122 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100122 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100122 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110122 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120122 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130122 Year of fee payment: 14 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |